Interestingly, the treatment was shown to prevent contralateral breast cancer by 50% and demonstrated a 44% risk reduction of developing a second breast cancer in both BRCA1 and BRCA2 WT and mutant conditions [88,89]. Here, BRCA2 is linked to breast carcinoma.